Peripheral T-cell lymphoma, not otherwise specified: a retrospective single-center analysis

Area of Science:

• Hematology
• Oncology
• Clinical Medicine

Background:

• Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is an aggressive hematologic malignancy.
• Limited data exists on the clinical characteristics and outcomes of PTCL-NOS in specific patient cohorts.

Purpose of the Study:

• To retrospectively analyze the clinical and pathological features, treatment strategies, and prognoses of patients diagnosed with PTCL-NOS.
• To evaluate the survival outcomes in a cohort of PTCL-NOS patients treated at Niigata University Medical and Dental Hospital.

Main Methods:

• Retrospective analysis of 28 patients with newly diagnosed PTCL-NOS.
• Data collected included patient demographics, International Prognostic Index (IPI) scores, treatment regimens (CHOP/THP-COP and third-generation chemotherapy), and follow-up data.
• Survival outcomes, including overall survival (OS) and progression-free survival (PFS), were calculated.

Main Results:

• The median age of the 28 patients (16 males, 12 females) was 62.5 years.
• 68% of patients had a high-intermediate or high IPI score, indicating advanced disease.
• At a median follow-up of 30 months, the 2-year OS rate was 61% and the 2-year PFS rate was 44%.

Conclusions:

• The study highlights the challenging prognosis of PTCL-NOS, with a significant proportion of patients presenting with high-risk features.
• Current chemotherapy regimens yield modest survival rates, underscoring the need for novel therapeutic approaches.
• Further investigation into novel agents for PTCL-NOS treatment is warranted to improve patient outcomes.